Simple Science

Cutting edge science explained simply

# Biology # Physiology

Connecting Metabolic Dysfunction and Bone Health

Investigating the link between MASLD and bone health issues.

Galen M Goldscheitter, Mulugeta Seneshaw, Faridoddin Mirshahi, Evan G Buettmann, Damian C Genetos, Arun J Sanyal, Henry J Donahue

― 6 min read


Bone Health and MASLD Bone Health and MASLD Link bone health. Exploring how liver disease impacts
Table of Contents

Metabolic Dysfunction-Associated Steatotic Liver Disease, or MASLD for short, is a condition that affects about 30% of people worldwide. Think of it as your liver getting a bit too cozy with fat, which can lead to a range of issues. Here’s the kicker: it has no cure, and it’s becoming more common by the day. For around 25% of those with MASLD, the situation gets worse, leading to complications like liver Inflammation, cirrhosis, liver failure, or even liver cancer. All of these come with a side dish of weak bones and a higher risk of fractures.

So, why should we care? Well, when people with MASLD suffer from fractures, it leads to more hospital visits, higher health care costs, and, unfortunately, a greater chance of death. This makes it crucial to handle bone health carefully in those with MASLD, but the reasons behind this connection are still not completely clear. Until we grasp what’s really going on, it’s tough to come up with effective treatments.

The Role of the Liver in Bone Health

Our liver isn’t just a filtering machine; it plays several important roles in keeping our bones strong. It helps with how our body processes energy and important nutrients, produces vitamin D, and manages hormones related to bone health. In people with MASLD, these functions can go haywire, which can lead to poor bone health.

On top of this, MASLD tends to increase inflammation in the body, marked by higher levels of certain harmful substances. These substances have a knack for causing bone loss. However, we still don’t have a complete picture of how all these factors tie into the bone problems seen in MASLD.

Interestingly, there’s a treatment called Denosumab that aims to help with bone issues connected to MASLD, but it’s not a perfect solution. It’s meant for people already suffering from osteoporosis or certain types of bone cancer. Plus, it’s pricey and loses its effectiveness over time.

We really need to think of better ways to prevent bone loss in people with MASLD and find a good model to study how the liver and bones interact.

Introducing the DIAMOND Mouse Model

Researchers have often struggled to find an accurate animal model to study MASLD. Enter the DIAMOND mouse! This little guy develops liver disease simply by eating a high-fat, high-sugar diet-just like many humans do. This mouse strain mimics both the disease and the genetic factors seen in human MASLD sufferers.

The DIAMOND mouse can develop obesity, insulin resistance, and other common issues found in people with MASLD after just a few weeks on a Western diet. After a few months, it can even reach advanced stages of liver damage, including cirrhosis and liver cancer. This makes the DIAMOND mouse a fantastic resource for studying not just the liver, but also the bone health of MASLD patients.

Male vs. Female: The Bone Battle

Research shows that MASLD can affect both men and women, but the effects on bone health may differ based on sex. For example, estrogen, a hormone that women have in higher amounts, helps protect bones from breaking down. This is why some studies suggest that women might be less prone to bone issues as a result of MASLD compared to men.

Current studies have shown that male DIAMOND mice with MASLD tend to lose bone mass over time when given a fat-rich diet, while female mice seem to hold onto their bone health a bit better. While males showed clear signs of weakening bones, female mice on the same diet maintained their bone structure and strength. This difference is something researchers are keen to understand further.

What’s Happening in the Bones?

In male DIAMOND mice, the early stages of MASLD lead to noticeable bone loss in the trabecular bone (the spongy part inside the bone) as early as 16 weeks into the diet. However, once the damage is done, the bone loss seems to stabilize. This means that while there’s a rapid loss of bone in the beginning, it doesn’t get much worse after that point.

When looking at the cortical bone (the solid outer layer), researchers found that significant bone thinning didn’t show up until 48 weeks of the Western diet. The changes in the cortical bones were correlated with reduced strength in terms of how much force the bones could handle before breaking.

The Bone Quality Debate

Researchers measured the structural and mechanical strength of the bones to better understand how MASLD impacts them. They found that while younger mice might seem strong, the longer they were on the bad diet, the weaker their bones became. So, it’s a bit like a college student living on junk food-initially, they might feel fine, but over time, it shows!

The Search for Answers: Potential Gene Connections

Scientists also began to explore the potential genes involved in driving the bone issues linked to MASLD. They used special computer programs to look for "ligands," which are like chemical messengers secreted by the liver that might affect bone activity.

Some interesting candidates popped up: genes like Ctgf, Rarres2, Anxa2, Fgf21, and Mmp13. These genes are involved in various processes that can impact bone health. For example, Ctgf has been linked to bone loss, while Rarres2 is associated with increased bone breakdown.

Wrapping It Up: The Bigger Picture

Overall, our understanding of the relationship between MASLD, bone health, and the differences between sexes is just beginning to unfold. While male DIAMOND mice show significant changes in bone health, female mice appear to have some protective mechanisms.

Research into this area is essential, not only to understand why some people with MASLD might have better bone health than others, but also to identify potential new treatment targets. As MASLD becomes more common, the need for effective management strategies increases, especially to prevent related issues like fractures and hospitalizations.

In a world where many people are dealing with the consequences of unhealthy lifestyles, understanding MASLD and its connection to bone health could pave the way for better health outcomes. And who knows? Maybe one day, the research we’re doing today will offer hope and solutions for millions affected by this condition. Until then, let’s make sure to take care of our livers, bones, and, of course, our diets!

Original Source

Title: Sexual dimorphism of MASLD-driven bone loss

Abstract: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is highly prevalent with major risk of progression to Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Hepatocellular Carcinoma (HCC). Recently, osteoporosis and bone fracture have emerged as sexually-dimorphic comorbidities of MASLD yet the mechanisms of this bone loss are unknown. Herein, we address these knowledge gaps using DIAMOND mice which develop MASLD, MASH, and HCC via Western diet exposure. We examined the skeletal phenotype of male DIAMOND mice after 16, 36, and 48 weeks of exposure to Western or control diet. At 16 weeks, male DIAMOND mice with MASLD lose trabecular bone but retain mechanical bone integrity. At 48 weeks, males lose cortical bone and mechanical integrity, indicating severe skeletal weakening. Female DIAMOND mice were protected from cortical and trabecular MASLD-associated bone loss and skeletal fragility at all timepoints. Using NicheNet, a publicly available database of hepatic mRNA expression in DIAMOND mice, and a PTH-induced model of bone loss, we suggest Ctgf, Rarres2, Anxa2, Fgf21, and Mmp13 are liver-secreted ligands inducing bone resorption. This study is the first preclinical investigation of bone loss in MASLD, and the first to suggest the role of Ctgf, Rarrest2, Anxa2, Fgf21, and Mmp13 as drivers of this pathology.

Authors: Galen M Goldscheitter, Mulugeta Seneshaw, Faridoddin Mirshahi, Evan G Buettmann, Damian C Genetos, Arun J Sanyal, Henry J Donahue

Last Update: 2024-11-28 00:00:00

Language: English

Source URL: https://www.biorxiv.org/content/10.1101/2024.11.25.625246

Source PDF: https://www.biorxiv.org/content/10.1101/2024.11.25.625246.full.pdf

Licence: https://creativecommons.org/licenses/by-nc/4.0/

Changes: This summary was created with assistance from AI and may have inaccuracies. For accurate information, please refer to the original source documents linked here.

Thank you to biorxiv for use of its open access interoperability.

Similar Articles